HCV Subtype Characterization among Injection Drug Users: Implication for a Crucial Role of Zhenjiang in HCV Transmission in China

被引:36
|
作者
Zhang, Chiyu [1 ]
Wu, Nana [1 ]
Liu, Jun [1 ]
Ge, Qinjuan [2 ]
Huang, Yan [1 ]
Ren, Qian [1 ]
Feng, Qingchuan [1 ,3 ]
He, Guangli [2 ]
机构
[1] Jiangsu Univ, Inst Life Sci, Jiangsu, Peoples R China
[2] Zhenjiang Ctr Dis Control & Prevent, Jiangsu, Peoples R China
[3] Zhengzhou Univ, Coll Basic Med, Dept Cell Biol & Med Genet, Zhengzhou, Herts, Peoples R China
来源
PLOS ONE | 2011年 / 6卷 / 02期
关键词
HEPATITIS-C-VIRUS; GENOTYPE DISTRIBUTION; GENETIC DIVERSITY; HIGH PREVALENCE; HEROIN USERS; HIV-1; EPIDEMIOLOGY; INFECTION; COINFECTION; SPREAD;
D O I
10.1371/journal.pone.0016817
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: HCV transmission is closely associated with drug-trafficking routes in China. However, the transmission route of HCV in Eastern China remains unclear. Here, we investigate the role of Zhenjiang city of Jiangsu province, an important transportation hub linking Shanghai with other regions of China, in HCV transmission. Methodology/Principal Findings: A total of 141 whole blood samples were collected from injection drug users (IDUs) in Zhenjiang and then tested for HCV infection. Of them, 115 HCV positive plasmas were subjected to RNA extraction, RT-PCR amplification, and sequencing. The subtype characterization and the evolutionary origin of HCV strains circulating in Zhenjiang were determined using polygenetic or phylogeographic analyses. Seven HCV subtypes 1b, 2a, 3a, 3b, 6a, 6e and 6n were detected among Zhenjiang IDUs, showing a complex HCV epidemic. The most predominant subtypes were 3a (38%) and 1b (26.8%). Among these subtypes, subtypes 3b, 6n and 6e originated from Southwestern China (i.e., Yunnan and/or Guangxi), subtypes 2a and 6a from Southern China (i.e., Guangdong), subtype 1b from Central (i.e., Henan) and Northwestern (i.e., Xinjiang) China, and subtype 3a from Southwestern (i.e., Yunnan) and Northwestern (i.e., Xinjiang) China. From Zhenjiang, subtypes 1b and 2a were further spread to Eastern (i.e., Shanghai) and Northern (i.e., Beijing) China, respectively. Conclusions/Significance: The mixing of seven HCV subtypes in Zhenjiang from all quarters of China indicates that as an important middle station, Zhenjiang plays a crucial role in HCV transmission, just as it is important in population migration between other regions of China and Eastern China.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] HCV treatment outcomes among current and remote injection drug users: Real- life data
    Conway, Brian
    Magel, Tianna
    Holeksa, Julie
    Thiam, Astou
    Yung, Rossitta
    Chu, Letitia
    Truong, David
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E214 - E215
  • [42] High prevalence of HIV and HCV infection among women who are non-injection drug users
    Ross, Elizabeth
    Raicht, Robert F.
    Dominelli, Frank
    Bini, Edmund J.
    HEPATOLOGY, 2006, 44 (04) : 290A - 291A
  • [43] Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUS) in Vancouver, Canada
    Grebely, J.
    Conway, B.
    Raffa, J.
    Lai, C.
    Krajden, M.
    Tyndall, M. W.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S214 - S215
  • [44] SHBG, Bone Mineral Density, and Physical Function Among Injection Drug Users With and Without HIV and HCV
    Dias, Jenny Pena
    Piggott, Damani A.
    Sun, Jing
    Wehbeh, Leen
    Garza, Joshua
    Abraham, Alison
    Astemborski, Jacquie
    Moseley, Kendall F.
    Basaria, Shehzad
    Varadhan, Ravi
    Brown, Todd T.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07): : E2971 - E2981
  • [45] Hepatitis C Virus (HCV)-Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection
    Thurairajah, Prem H.
    Hegazy, Doha
    Chokshi, Shilpa
    Shaw, Steve
    Demaine, Andrew
    Kaminski, Edward R.
    Naoumov, Nikolai V.
    Cramp, Matthew E.
    JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (12): : 1749 - 1755
  • [46] Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in Thai injection drug users
    Netski, DM
    Wang, XH
    Mehta, SH
    Nelson, K
    Celentano, D
    Thongsawat, S
    Maneekarn, N
    Suriyanon, V
    Jittiwutikorn, J
    Thomas, DL
    Ticehurst, JR
    JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) : 1631 - 1636
  • [47] Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV
    Kresina, TF
    Bruce, RD
    Cargill, VA
    Cheever, LW
    CLINICAL INFECTIOUS DISEASES, 2005, 41 : S83 - S88
  • [48] HCV therapy as part of an interdisciplinary low-threshold harm reduction strategy in HCV infected injection drug users
    Valencia, Jorge A.
    Cuevas, Guillermo
    Troya, Jesus
    Morro, Angela
    Gutierrez, Jorge
    Vazquez-Moron, Sonia
    Ryan, Pablo
    HEPATOLOGY, 2017, 66 : 616A - 616A
  • [49] Need-adapted HCV-treatment setting for injection drug users
    Reimer, Jens
    Haasen, Christian
    LANCET, 2009, 373 (9681): : 2090 - 2091
  • [50] Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection
    Dore, GJ
    Thomas, DL
    SEMINARS IN LIVER DISEASE, 2005, 25 (01) : 18 - 32